ReviewTrends in immunology2017
PSGL-1: A New Player in the Immune Checkpoint Landscape.
Review in Trends in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 152 citations in OpenAlex.
- PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma.bioRxiv : the preprint server for biology · 2026Article
- Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.Cancer research communications · 2026Article
- LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.iScience · 2026Article
- Lipid alterations and endothelial dysfunction are associated with multiple sclerosis pathophysiology.Scientific reports · 2026Article
- Transcriptome combined with single-cell data to construct a prognostic model for glycosylation-related genes in osteosarcoma.Discover oncology · 2026Article
- VISTA: bridging gaps in cancer immunotherapy.Discover oncology · 2026Review
- Dysregulated expression of PSGL-1 and ADAM8 in Sjögren's disease: potential contribution to disease pathogenesis.Frontiers in immunology · 2026Article
- Transcriptomic characterization of platelet-rich fibrin-induced macrophage responses identifies U937 cells as a sensitive bioassay.Frontiers in immunology · 2026Article
- Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments.Frontiers in oncology · 2026Review
- VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies.Immune network · 2025Review
- Granulocyte colony-stimulating factor induced T-cell hyporesponsiveness via modulation of CD177Clinical and translational medicine · 2025Article
- Different neutrophil extracellular trap related Ewing sarcoma subtypes exhibit distinct prognosis, and immune microenvironment characteristics.Scientific reports · 2025Article
- Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases.Journal of clinical medicine · 2025Review
- The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025Review
- Comprehensive analysis of SELPLG as a potential immunotherapy target and prognostic biomarker in oncology.Discover oncology · 2025Article
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.The breast journal · 2025Review
- Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model.Frontiers in immunology · 2025Article
- Immune inhibitory receptor agonist therapeutics.Frontiers in immunology · 2025Review
- Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
P-selectin glycoprotein ligand-1 (PSGL-1) has long been studied as an adhesion molecule involved in immune cell trafficking and is recognized as a regulator of many facets of immune responses by myeloid cells. PSGL-1 also regulates T cell migration during homeostasis and inflammatory settings. However, recent findings indicate that PSGL-1 can also negatively regulate T cell function. Because T cell differentiation is finely tuned by multiple positive and negative regulatory signals that appropriately scale the magnitude of the immune response, PSGL-1 has emerged as an important checkpoint during this process. We summarize what is known regarding PSGL-1 structure and function and highlight how it may act as an immune checkpoint inhibitor in T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.